2-Aminooctadeca-3,5-dien-1-OL | 74070-73-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Aminooctadeca-3,5-dien-1-OL
• 英文别名: 2-aminooctadeca-3,5-dien-1-ol
• CAS: 74070-73-8
• 化学式: C₁₈H₃₅NO
• 分子量: 281.5
• InChiKey: YWJKMMURCWZLDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• USE OF SM_SPHINGOMYELIN (D18:1, C16:0) AS A MARKER FOR HEART FAILURE
  申请人：metanomics GmbH

  公开号：EP3190418A1

  公开（公告）日：2017-07-12

  The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject and a method for monitoring progression or regression of heart failure in a subject. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

  本发明涉及诊断方法领域。具体而言，本发明涉及一种诊断受试者心力衰竭的方法和一种监测受试者心力衰竭进展或消退的方法。本发明还涉及执行上述方法的工具，如诊断设备。
• MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER IN A SUBJECT
  申请人：metanomics Health GmbH

  公开号：EP3486657A2

  公开（公告）日：2019-05-22

  The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing pancreatic cancer in a subject, a method for identifying whether a subject is in need for a therapy of pancreatic cancer or a method for determining whether a pancreatic cancer therapy is successful. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

  本发明涉及诊断方法领域。具体而言，本发明涉及一种诊断受试者胰腺癌的方法、一种确定受试者是否需要胰腺癌治疗的方法或一种确定胰腺癌治疗是否成功的方法。本发明还涉及用于实施上述方法的工具，如诊断设备。
• METHOD FOR THE ASSESSMENT OF NAFLD
  申请人：metanomics Health GmbH

  公开号：EP3502703A1

  公开（公告）日：2019-06-26

  The present invention relates to a method for assessing non-alcoholic fatty liver disease (NAFLD) comprising determining in a sample from a subject suffering from NAFLD at least the amounts of two metabolite biomarkers, wherein said two metabolite biomarkers are: (i) at least one eicosatrienoic acid metabolite biomarker and (ii) at least one androgen metabolite biomarker and/or at least one bile acid metabolite biomarker. Further, the present invention relates to the vitro use of the two metabolite biomarkers for assessing non-alcoholic fatty liver disease (NAFLD).

  本发明涉及一种评估非酒精性脂肪肝（NAFLD）的方法，该方法包括测定非酒精性脂肪肝患者样本中至少两种代谢物生物标志物的含量，其中所述两种代谢物生物标志物是：(i) 至少一种二十碳三烯酸代谢物生物标志物；(ii) 至少一种雄激素代谢物生物标志物和/或至少一种胆汁酸代谢物生物标志物：(i) 至少一种二十碳三烯酸代谢物生物标志物和 (ii) 至少一种雄性激素代谢物生物标志物和/或至少一种胆汁酸代谢物生物标志物。此外，本发明还涉及体外使用这两种代谢物生物标志物评估非酒精性脂肪肝（NAFLD）。
• USE OF SM_SPHINGOMYELIN (D18:1, C23:1) AS A MARKER FOR HEART FAILURE
  申请人：metanomics GmbH

  公开号：EP3527990A1

  公开（公告）日：2019-08-21

  The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject and a method for monitoring progression or regression of heart failure in a subject. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

  本发明涉及诊断方法领域。具体而言，本发明涉及一种诊断受试者心力衰竭的方法和一种监测受试者心力衰竭进展或消退的方法。本发明还涉及执行上述方法的工具，如诊断设备。
• Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel
  申请人：METANOMICS HEALTH GMBH

  公开号：US10168333B2

  公开（公告）日：2019-01-01

  The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing pancreas cancer in a subject and, preferably for differentiating between pancreatic cancer and pancreatitis and a method for identifying whether a subject is in need for a therapy of pancreatic cancer. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

  本发明涉及诊断方法领域。具体而言，本发明考虑了一种诊断受试者胰腺癌的方法，最好是区分胰腺癌和胰腺炎的方法，以及一种确定受试者是否需要治疗胰腺癌的方法。本发明还涉及执行上述方法的工具，如诊断设备。